Cagrilintide 5mg

Cagrilintide — Research Overview

Introduction

Cagrilintide is a novel, long-acting amylin analogue currently under investigation for its effects on metabolic regulation and appetite control. Its structure features N-terminal lipidation, which enhances stability by binding to serum albumin, extending its circulating half-life. By mimicking and amplifying the actions of natural amylin, Cagrilintide has been studied for its influence across both homeostatic (energy balance) and hedonic (reward-driven) appetite regulation pathways.

Background and Mechanism

Amylin is a peptide hormone co-secreted with insulin by pancreatic beta cells and is involved in satiety, gastric emptying, and glucose regulation. Synthetic analogues such as Cagrilintide are designed to improve upon these natural effects while offering extended half-life and potency. Cagrilintide’s activity is thought to involve multiple signaling pathways:- Central satiety pathways: Enhancing satiety signaling in the hypothalamus to reduce caloric intake.- Gastrointestinal regulation: Slowing gastric emptying, prolonging nutrient absorption, and influencing blood glucose balance.- Hedonic appetite regulation: Interacting with reward-related circuits that influence cravings and non-homeostatic food intake. The structural modification with lipidation allows prolonged receptor engagement and pharmacological activity, which may offer advantages in chronic metabolic studies.

Chemical Characteristics

Research Applications

1. Weight Regulation and Appetite Control

– Preclinical and clinical studies of amylin analogues suggest reductions in body weight, decreased food intake, and improved metabolic markers.- Cagrilintide has been studied as a potential adjunct to other metabolic agents in weight management models.

2. Glucose and Metabolic Balance

– Amylin analogues have been shown to modulate gastric emptying and postprandial glucose excursions.- Cagrilintide’s longer half-life may improve consistency of these effects in extended dosing regimens.

3. Combination Therapy Potential

– Ongoing research explores the use of Cagrilintide in combination with incretin-based therapies (e.g., GLP-1 receptor agonists), with preliminary data suggesting additive or synergistic benefits in weight and glucose regulation.

Lyophilized Formulation

Our Cagrilintide is supplied as a lyophilized (freeze-dried) powder to ensure stability, extended shelf life, and purity. This form allows for precise reconstitution in laboratory settings without fillers or excipients.

Cagrilintide — References

Frias, J. P., Nauck, M. A., Van J, et al. Efficacy and safety of cagrilintide alone and in combination with semaglutide in people with overweight and obesity: A multicentre, double-blind, placebo-controlled, randomised phase 2 trial. The Lancet. 2021;398(10300): 1975–1988. https://doi.org/10.1016/S0140-6736(21)02316-3

Nauck, M. A., Marre, M., Perdomo, C. M., et al. Cagrilintide, a novel amylin analogue, for the treatment of obesity and type 2 diabetes: Mechanisms and clinical potential. Diabetes, Obesity and Metabolism. 2022;24(7):1239–1249. https://doi.org/10.1111/dom.14714

Kapitza, C., Nosek, L., Jensen, L., Hartvig, H., Jensen, C. B. Cagrilintide, a long-acting amylin analogue: Results of single and multiple ascending dose trials in healthy individuals and overweight people. Diabetes, Obesity and Metabolism. 2020;22(8):1406–1416. https://doi.org/10.1111/dom.14044

Blundell, J. E., Finlayson, G., Axelsen, M., Flint, A. Effects of cagrilintide and semaglutide on appetite, energy intake, and food preferences in adults with overweight or obesity: A randomized crossover trial. Diabetes, Obesity and Metabolism. 2022;24(9):1797–1807. https://doi.org/10.1111/dom.14797

Anderson, S. L. Cagrilintide: A new potential anti-obesity medication. Annals of Pharmacotherapy. 2023;57(5):620–629. https://doi.org/10.1177/10600280221146957

Novo Nordisk. Cagrilintide — Mechanism of action and clinical development program. Company clinical summary. 2023.

NOTICE OF COMPLIANCE

The mission of BioGenix Peptides™ is to provide researchers with the highest-quality, Ultra-Pure Series™ compounds to help unlock the full potential of this evolving field. With precision, purity, and scientific integrity at the core of our operations, BioGenix Peptides™ is dedicated to supporting responsible exploration and discovery

Products from BioGenix Peptides™ are not intended for human consumption. They are supplied exclusively for in-vitro and pre-clinical research purposes.

By purchasing or using these products, the Customer accepts full responsibility for their handling and use, and agrees to indemnify and hold BioGenix Peptides™ harmless from any claims resulting from misuse